India grants country's first ever compulsory licence - for Bayer's Nexavar
This article was originally published in SRA
Executive Summary
India has granted its first-ever compulsory licence in medicines with the issuing of an order that gives the Indian generics and biosimilar producer NATCO Pharma the right to produce and market a version of Bayer's anticancer, Nexavar (sorafenib tosylate), in the country1,2.